EnteroMedics (NASDAQ:ETRM) is developing a vagus-nerve stimulator to address obesity, and is facing a panel of medical experts Tuesday, June 17th, who will make recommendations about its Maestro device to the FDA for/against its approval for the US market. In recent years, ETRM has conducted two Phase III trials on the device, both of which clearly missed all their efficacy endpoints, resulting in the stock losing 97%+ of its price (from about $30 down to about $0.85). Yet, company PR, a small handful of analysts and some interpretations of recent stock action claim good reason for likelihood of approval nonetheless. A close and sober look at the clinical context is called for.
Phase-III trials' results and trial design...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|
|PRO Top long ideas returned 21.7% in 2016**|